Moderna spent four years being the cautionary tale of the pandemic trade. On Wednesday morning it delivered the result the entire mRNA field has been waiting on, and the stock went up roughly fifty percent before the opening bell.
Moderna and Merck announced that their Phase 3 trial of a personalized mRNA cancer vaccine met its primary endpoint in melanoma. It is the first Phase 3 success for an individualized neoantigen therapy and the first for any mRNA based cancer therapy.
What Was Announced
The trial is called INTerpath 001. It tested intismeran autogene, Moderna’s individualized neoantigen therapy, in combination with Merck’s Keytruda, against Keytruda on its own.
The combination met the primary endpoint of recurrence free survival and the key secondary endpoint of distant metastasis free survival, both with statistically significant improvements. No new safety signals were reported.
Who Was in the Trial
The study enrolled 1,089 patients with resected stage IIB through IV melanoma. These are people who have had a tumor removed and whose central medical problem is whether the cancer comes back.
That framing matters. This is not a treatment aimed at shrinking an existing tumor. It is adjuvant therapy designed to stop recurrence, which is the part of melanoma care where the outcomes have been stubborn.
How a Personalized Cancer Vaccine Actually Works
A neoantigen is a protein fragment that appears on cancer cells because of mutations specific to that tumor. Every patient’s set is different.
The process sequences a patient’s own tumor, identifies the neoantigens most likely to provoke an immune response, and builds a bespoke mRNA product that instructs the body to make those fragments. The immune system then learns to recognize and attack cells carrying them. Keytruda’s job is to take the brakes off the T cells so they can act on what the vaccine taught them.
Each dose is manufactured for one person. That is the promise and also the manufacturing problem.
The Numbers Nobody Has Released Yet
Here is the thing to be careful about, because a lot of coverage is already blurring it. The companies said the trial hit its endpoints. They did not release hazard ratios or effect sizes. Those go to an upcoming medical meeting.
You will see figures of 49 percent and 59 percent attached to this story today. Those come from the five year Phase 2b data presented at ASCO in June, from a smaller earlier trial. They are real numbers from real research, but they are not the Phase 3 result. Anyone putting a percentage on today’s readout is guessing.
What the Stock Did
MRNA closed Tuesday at $62.96, down 2.33 percent. In premarket trading Wednesday it ran to roughly $97 to $100, a move of about fifty to sixty percent. Merck shares rose as well.
For context on how far the stock had fallen, its 52 week range going into Wednesday was $22.28 to $85.60. Analyst consensus was a Hold with a price target near $51, which the premarket price blew through by nearly double. That gap between what analysts modeled and what happened is the real story of the morning. For more on how a single day can reset a company’s market narrative, see our coverage of Nike hitting a fresh low on its new CFO’s first day.
Why This Matters Beyond Melanoma
Melanoma was the proving ground, not the destination. Moderna has nine ongoing Phase 2 and Phase 3 trials using this platform across melanoma, non small cell lung cancer, bladder cancer and renal cell carcinoma.
The reason today’s result moved the whole sector is that it validates the approach rather than one product. If individualized mRNA therapy works in one solid tumor, the argument for testing it in others gets much harder to dismiss.
The Redemption Arc Nobody Scripted
Moderna’s revenue is down sharply from its pandemic peak and the company has spent years cutting costs while insisting the mRNA platform was worth more than one vaccine. That argument was expensive and unpopular.
The company also won FDA approval earlier this month for an mRNA flu vaccine for adults 50 and older, a separate development that got a fraction of the attention. Wednesday is the day the oncology bet stopped being a slide in an investor deck.
What Happens Next
Full data goes to a medical meeting that has not been named. Regulatory submission is planned but no filing date has been given, and no approval timeline exists yet.
Manufacturing is the open question that will not show up in a press release. Building an individualized product for every patient at commercial scale is a logistics problem no oncology drug has ever had to solve. That, more than the science, is what determines whether this reaches people.
There is also a pricing conversation coming that nobody has started yet. A therapy manufactured individually for each patient does not fit the economics of a mass produced drug, and payers have never had to evaluate anything shaped like this. Those arguments tend to arrive about a year after the science does.
Frequently Asked Questions
What did Moderna and Merck announce?
That their Phase 3 trial of a personalized mRNA cancer vaccine combined with Keytruda met its primary endpoint of recurrence free survival in melanoma patients.
Is this a cure for cancer?
No. It is an adjuvant therapy aimed at reducing the chance melanoma returns after surgery, tested in one cancer type, and it has not been approved by any regulator.
How much did MRNA stock move?
Shares closed at $62.96 Tuesday and traded around $97 to $100 in Wednesday premarket, a gain of roughly fifty to sixty percent.
What is intismeran autogene?
Moderna’s individualized neoantigen therapy, previously known as mRNA-4157 and V940. It is custom built from each patient’s own tumor sequencing.
When will the full trial data be released?
At an upcoming medical meeting. The companies have not named it or given a date, and effect sizes have not been disclosed.
Which other cancers is this being tested in?
Non small cell lung cancer, bladder cancer and renal cell carcinoma, among others, across nine ongoing Phase 2 and Phase 3 trials.
